Progress in engineered bacterial cancer therapies.

Area of Science:

• Oncology
• Synthetic Biology
• Immunology

Background:

• Engineered bacteria are increasingly utilized in cancer therapy development.
• Advances in synthetic biology and tumor immunology drive this field.
• These microbes selectively colonize solid tumors.

Purpose of the Study:

• To review recent progress in engineered bacteria for cancer therapy.
• To focus on engineering strategies and their efficacy in preclinical models.
• To outline future prospects and challenges in the field.

Main Methods:

• Engineering bacteria to secrete therapeutic agents (toxins, proteins).
• Programming bacteria for targeted intracellular delivery.
• Developing bacteria that sense tumor-specific metabolites and antigens for enhanced selectivity and safety.

Main Results:

• Engineered bacteria induce tumor cell death and activate anti-tumor immune responses.
• These microbes synergize with immunotherapies like immune checkpoint inhibitors and CAR-T cells.
• Engineered strains stimulate innate and adaptive immunity, including at metastatic sites.

Conclusions:

• Engineered bacteria represent a promising platform for cancer treatment.
• Further development is needed to address remaining challenges for clinical translation.
• This approach holds potential for enhancing existing cancer therapies and overcoming treatment resistance.